EGFR and pneumonitis: A prospective cohort study of drug-induced pneumonitis after erlotinib administration in patients with EGFR mutation-positive NSCLC identified pre-existing IP and low residual normal lung function (50% or less) as risk factors for developing drug-induced pneumonitis.